Media Coverage

Several large healthcare organizations have announced they have signed on to Google Cloud for Gemini-powered AI agents for patient engagement, improved workflows, revenue cycle capabilities and easier-to-read lab results. At HIMSS26, Google Cloud will show how agentic AI can lead healthcare organizations from siloed data entry to automated results. Quest Diagnostics, which offers diagnostic information services, has announced Quest AI Companion, a new AI-powered chat feature that helps individuals understand Quest laboratory test results. Through the app and portal MyQuest, individuals can ask questions about their test results and receive explanations in a HIPAA-compliant solution.

Quest Diagnostics is launching a chatbot tailored for laboratory test results as it seeks to allow patients the ability to come to terms with their findings and perform deeper dives on their own health. The Quest AI Companion can probe data from patients’ labs for up to five years in order “to help explain results and uncover potential health risks,” according to a March 2 statement.

Quest Diagnostics, a leading provider of diagnostic information services with headquarters in Secaucus, announced that Benjamin Beauvalot has joined the company as senior vice president, chief strategy and M&A officer. “Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class health care organizations,” Davis said.

Quest Diagnostics said its Flow Cytometry MRD for Myeloma test detects minimal residual disease (MRD), the small number of cancer cells that can remain in the body after treatment and potentially lead to relapse, “at a fraction of the cost” of other methods. “Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system,” Yuri Fesko, MD, Quest’s senior vice president and chief medical officer, said in a company press release.

In 2020, as many as 5.8 million Americans were living with Alzheimer’s Disease (AD)—a number projected to nearly triple to 14 million people by 2060.1 As changes in the brain can begin years before the first symptoms appear, the science around assessing risk and diagnosing AD and other dementias is complex and continues to evolve with the publication of new research. (By Michael K. Racke, MD)

Quest Diagnostics reported Tuesday a 7 percent year-over-year increase in its Q4 2025 revenue. Revenue for the three months ended Dec. 31, 2025, was $2.81 billion, up from $2.62 billion in the same quarter last year and above the consensus Wall Street estimate of $2.76 billion. Requisition volumes rose 9 percent during the quarter while revenue per requisition fell less than 1 percent. Organic requisition volume rose 8 percent year over year, the Secaucus, New Jersey-based company said.

Forever chemicals. They’re everywhere — from non-stick pans to seafood to cosmetics. 25 Investigates worked with Quest Diagnostics, which offers a PFAS blood panel that screens for nine common forever chemicals for $350. Quest allowed us to film most of my blood test. We went in before the lab opened one January morning to protect patient privacy. Kavanaugh found the test itself to be quick and painless — just one vial of blood. Quest says it began offering the PFAS blood test in 2024. Quest says theirs is the first PFAS blood test available as a consumer-initiated test with physician oversight based on recommendations by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations.

Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine.